Loading...

Revelation Biosciences, Inc.

REVBW•NASDAQ
Healthcare
Biotechnology
$0.01
$-0.00(-17.81%)

Revelation Biosciences, Inc. (REVBW) Stock Overview

Explore Revelation Biosciences, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 62.2/100

Key Financials

Market Cap1.5M
P/E Ratio-0.05
EPS (TTM)$-4.77
ROE-0.01%
Fundamental Analysis

AI Price Forecasts

1 Week$0.01
1 Month$0.02
3 Months$0.00
1 Year Target$0.00

REVBW Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Revelation Biosciences, Inc. (REVBW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.05 and a market capitalization of 1.5M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for REVBWStats details for REVBW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for REVBWAnalyst Recommendations details for REVBW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Revelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease. The company's lead therapeutic candidate is REVTx-99, an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses, such as SARS-CoV-2 comprising its variants, influenza A and B, parainfluenza, rhinovirus, and RSV, as well as is being developed for other indications comprising allergic rhinitis and chronic nasal congestion. It also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for immunity; and REVDx-501, a rapid home use diagnostic to detect respiratory viral infection. The company was founded in 2019 and is based in New York, New York.

CEO

James M. Rolke

Employees

8

Headquarters

5 West 21st Street, San Diego, NY

Founded

1970

Frequently Asked Questions

;